je.st
news
Tag: therapeutic
Galderma Rolls Out Therapeutic Skin Care Line
2015-10-08 07:00:00| Happi Breaking News
Excipial topicals and oral supplement are engineered for challenged skin.
Tags: line
care
skin
therapeutic
Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-06-03 06:41:56| drugdiscoveryonline Home Page
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, an investigational RNAi therapeutic, for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)
Tags: united
states
united states
food
New clinical platform may accelerate discovery of diagnostic and therapeutic agents
2015-04-11 09:03:26| Biotech - Topix.net
Researchers have developed a new technology that enables rapid discovery of aptamers, one of the fastest growing classes of diagnostic and therapeutic agents. Aptamers are short sequences of genetic material that fold into precise 3-D structures that bind target molecules and inhibit their biological functions.
Tags: agents
platform
clinical
discovery
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302
2015-04-01 08:23:10| drugdiscoveryonline Home Page
Therapure Innovations, a division of Therapure Biopharma Inc., recently announces that the U.S. Food and Drug Administration (FDA) has given the company approval to proceed with a Phase 1 clinical trial of TBI 302, a targeted therapeutic for the treatment of liver cancer
Tags: trial
phase
approval
cancer
BIO Study looks at venture funding for therapeutic innovation.
2015-02-13 14:30:24| Industrial Newsroom - All News for Today
BIO released study on venture financing broken down by disease area and novelty of research from 2004–2013. Study found that 78% of U.S. venture investment for therapeutics went toward novel drug R&D, suggesting innovation is core priority for investors. Disease areas affecting large populations – Diabetes, Psychiatry, Gastrointestinal, Respiratory, and Cardiovascular – have seen decline in novel drug R&D venture funding, while rare disease funding has seen large increase over past decade.
Tags: study
bio
funding
innovation